 CELEBRATION, Fla., Dec. 02, 2020 GLOBE NEWSWIRE -- KemPharm, Inc. OTCQB: KMPH, a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020, with the U.S. Food and Drug Administration FDA, or the Agency regarding the ongoing review of the New Drug Application NDA for KP415, KemPharms investigational product candidate for the treatment of attention deficit hyperactivity disorder ADHD. In the meeting, the FDA did not raise any substantive issues related to KP415s safety and efficacy at this point in their review of the KP415 NDA. In addition, the FDA re-affirmed the PDUFA date for the KP415 NDA is March 2, 2021. 